Centene Corporation (NYSE:CNC) Soars on Strong Q1 Earnings and Raised Profit Outlook

• Centene Corporation (NYSE:CNC) reported robust first-quarter results, with adjusted EPS of $3.37 significantly surpassing analyst expectations of $2.23.
• The healthcare provider achieved substantial revenue growth, with total revenue increasing by 7.1% to $49.94 billion, driven by strong performance in its Medicaid and Medicare segments.
• Analysts at Raymond James set a new price target of $60.00 for Centene, reflecting a potential upside of over 21%, as the company raised its 2026 adjusted profit forecast to greater than $3.40 per share due to effective cost management.

Centene Corporation (NYSE:CNC) is a major health insurance company that focuses on providing government-sponsored healthcare plans. Its main business involves offering Medicaid and Medicare programs. As a managed-care company, Centene works to control healthcare costs for its members while maintaining the quality of medical services provided.

Following strong quarterly results, analyst Sarah James from Raymond James sets a new price target for Centene at $60.00. With the stock trading at $49.57, this new target represents a potential increase of approximately 21.04%. This optimism is supported by the company's recent financial performance and improved cost management.

The company reports strong first-quarter results, with net earnings rising to $1.54 billion. Its adjusted earnings per share (EPS), which shows profit per share after certain adjustments, reaches $3.37. This figure significantly beats analyst expectations of $2.23 per share, driven by successful efforts to manage medical costs.

Total revenue increases by 7.1% to $49.94 billion, also surpassing Wall Street's forecast. This revenue growth is supported by its core government programs. Revenue from its Medicaid segment grows by 6% to $23.60 billion, while its Medicare segment sees a substantial 18% climb to $10.30 billion.

As highlighted by Reuters, Centene raises its 2026 adjusted profit forecast due to better control over medical costs. The company now projects a full-year adjusted diluted EPS of greater than $3.40. This updated guidance suggests confidence in its ability to manage expenses and improve profitability moving forward.